Aethlon Medical Cmn (AEMD) 6.28 $AEMD Aethlon Medical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aethlon Medical Cmn (AEMD) 6.28 $AEMD

Aethlon Medical Announces Fiscal 2017 First Quarter Results
PR Newswire - Thu Aug 11, 3:15PM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016.
AEMD: 6.28 (-0.20)

Aethlon Medical Announces Zika Virus Data
PR Newswire - Thu Aug 11, 8:12AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours.
AEMD: 6.28 (-0.20)

Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
PR Newswire - Tue Aug 09, 11:07AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)

Aethlon Medical Announces Issuance Of Exosome Capture Patent
PR Newswire - Tue Jun 14, 9:28AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent" , related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, including cancer.
AEMD: 6.28 (-0.20)

Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
PR Newswire - Mon Jun 06, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation, which is scheduled to begin at 10:45AM (PT), will review Aethlon Medical's initiatives to combat cancer and infectious disease. Mr. Joyce will also present the discovery of a non-invasive candidate biomarker to diagnose CTE that was made in collaboration with Exosome Sciences, a majority-owned subsidiary of Aethlon Medical. CTE is a neurological disorder associated with exposure to repetitive head impacts, such as those experienced by American football players. At present, CTE can only be definitively diagnosed through post-mortem autopsy. The presentation can be accessed on-line through the following link: http://www.veracast.com/webcasts/bio/internat...220202.cfm
AEMD: 6.28 (-0.20)

Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
PR Newswire - Wed Jun 01, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-investment-forum.html) at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL at 10:20 p.m. Central Time on Friday, June 3, 2016.
AEMD: 6.28 (-0.20)

Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report
Marketwired - Thu May 05, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.
AEMD: 6.28 (-0.20)

Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
PR Newswire - Wed May 04, 8:30AM CDT
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate production of its ELLSA(TM) (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic products.
AEMD: 6.28 (-0.20)

Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
PR Newswire - Mon May 02, 7:45AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.28 (-0.20)

FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce
PR Newswire - Tue Apr 05, 8:00AM CDT
www.FinancialBuzz.com, a leader in the financial media and news space, today announces an exclusive HD video interview with Aethlon Medical, Inc. (NASDAQ: AEMD) Chairman & CEO James Joyce from the floor of the NASDAQ MarketSite.
AEMD: 6.28 (-0.20)

Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
PR Newswire - Thu Mar 31, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient and has consented the enrollment of the next patient. The information was disclosed during an Annual Meeting of Stockholders conducted on March 29, 2016 in San Diego, California. Aethlon had previously disclosed in February 2016, that it had completed the formal training of its new principal investigator, Dr. Ronald Ralph, and had additionally trained two sub-principal investigators to support the advancement of its clinical study.
AEMD: 6.28 (-0.20)

Aethlon Medical, Inc. Reports Annual Meeting Results
PR Newswire - Wed Mar 30, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California.
AEMD: 6.28 (-0.20)

Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
PR Newswire - Wed Mar 09, 5:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30 p.m. ET) on Wednesday, March 16, 2016.
AEMD: 6.28 (-0.20)

Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
PR Newswire - Fri Feb 05, 8:32AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.
AEMD: 6.28 (-0.20)

Aethlon Medical Announces Fiscal 2016 Third Quarter Results
PR Newswire - Thu Feb 04, 3:10PM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fiscal 2016 ended December 31, 2015.
AEMD: 6.28 (-0.20)

Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
PR Newswire - Wed Feb 03, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.
AEMD: 6.28 (-0.20)

Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016.
AEMD: 6.28 (-0.20)

Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
PR Newswire - Fri Jan 29, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 53

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 26

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 135

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 32

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 69

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Artprice News Revolutionizes Global Art Market Information

Updated Category News Views 237

Artprice News Launch: A New Chapter in Art Market Reporting Artprice by Artmarket has introduced a groundbreaking initiative with the launch of Artprice News, marking a significant evolution in the landscape of art market information. This innovative news agency is tailored exclusively for the art world, broadcasting valuable insights in 11 languages and spanning 122...

Continue Reading
U-BX Technology Ltd. Responds to Nasdaq Notification on Listing

Updated Category News Views 211

U-BX Technology Ltd. Responds to Nasdaq Notification U-BX Technology Ltd. (NASDAQ: UBXG), recognized as a frontrunner in offering innovative services powered by artificial intelligence to the insurance sector, recently informed stakeholders regarding important notifications received from The Nasdaq Stock Market LLC. Details of Nasdaq Notification Letters On a recent date,...

Continue Reading
Understanding Investor Rights in Newmont Securities Class Action

Updated Category News Views 370

Understanding the Basics of the Newmont Class Action Investors who have sustained losses exceeding $50,000 in Newmont Corporation should take heed of an active class action. This legal effort aims to provide relief for those affected by adverse developments within the company. Faruqi & Faruqi, LLP, a prominent securities law firm, is at the forefront of this investigation...

Continue Reading
Tarte's Record-Breaking Collab: 60 Seconds to Sellout

Updated Category News Views 129

When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...

Continue Reading
What Lessons Can Traditional Investors Learn From the Rise of Ethereum?

Updated Category Crypto Views 3176

Turn the clock back a few decades, and investors on Wall Street would laugh if you tried to pitch the concept of blockchain to them. It’s one of those ideas that sound like they’d technically work but would be impossible to practically execute. Yet today, blockchain and cryptocurrency exist and are proof that the skeptics were wrong. Sadly, many traditional investors...

Continue Reading